We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ProBioGen, Inhibrx ink license agreement

ProBioGen, Inhibrx ink license agreement

October 25, 2011
CenterWatch Staff

ProBioGen and Inhibrx signed a multi-program license deal on ADCC-enhanced therapeutic antibodies. ProBioGen’s GlymaxX ADCC enhancement technology and mammalian cell line development and manufacturing services will be used to advance therapeutic antibodies generated by Inhibrx’s discovery platforms.

The agreement initially covers development services for several undisclosed first-in-class and best-in-class antibodies with enhanced ADCC potency, as well as cell line and process development for other recombinant therapeutic proteins. ProBioGen will receive both milestone-dependent license fees, as well as fee-for-service-based payments for its technologies and efforts. Further financial details were not disclosed.

"We are impressed with Inhibrx’s discovery platforms and their target selection expertise. This effort is a perfect match for the two companies’ complementary core expertise, enabling industrial discovery and development of a range of innovative therapeutic proteins” explained ProBioGen’s chief scientific officer, Dr Volker Sandig. Dr Wieland Wolf, CEO added “Inhibrx’s company culture is very similar to ours, pragmatic, technology and science-driven with the aim to leverage proprietary technologies and expertise. We are looking very much forward working together in this spirit.”

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing